^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Peripheral T-cell Lymphoma |
| Drug: | Ontak (denileukin diftitox) (IL-2 stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ANTICANCER AGENT “Remitoro® INTRAVENOUS DRIP INFUSION 300µg”(DENILEUKIN DIFTITOX (GENETIC RECOMBINANT)) APPROVED IN JAPAN FOR PERIPHERAL T-CELL LYMPHOMA AND CUTANEOUS T-CELL LYMPHOMA
Published date:
03/23/2021
Excerpt:
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has obtained manufacturing and marketing approval for the anticancer agent “Remitoro® for Intravenous Drip Infusion 300μg” (denileukin diftitox (genetic recombinant)) with the indications of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) and relapsed or refractory Cutaneous T-cell Lymphoma (CTCL), in Japan.
